Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This hypothesis-generating study (NCT01352585) explored the impact of JAK2(V617F) mutation status on treatment response to anagre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cascavilla, Nicola, De Stefano, Valerio, Pane, Fabrizio, Pancrazzi, Alessandro, Iurlo, Alessandra, Gobbi, Marco, Palandri, Francesca, Specchia, Giorgina, Liberati, A Marina, D’Adda, Mariella, Gaidano, Gianluca, Fjerza, Rajmonda, Achenbach, Heinrich, Smith, Jonathan, Wilde, Paul, Vannucchi, Alessandro M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441358/
https://www.ncbi.nlm.nih.gov/pubmed/26028965
http://dx.doi.org/10.2147/DDDT.S79576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441358/
https://www.ncbi.nlm.nih.gov/pubmed/26028965
http://dx.doi.org/10.2147/DDDT.S79576

Ejemplares similares